Skip to content
Onset indicators of Amyotrophic Lateral Sclerosis (ALS)
Onset indicators of Amyotrophic Lateral Sclerosis (ALS)

Signs of ALS emerging

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurological disorder that affects the motor neurons in the brain and spinal cord, leading to the loss of muscle control [1]. This article provides an overview of the current diagnostic methods and treatments for ALS.

Diagnosing ALS

Diagnosing ALS can be challenging for doctors, as it requires a series of tests and assessments to rule out other conditions. A neurological examination assesses a person's strength, reflexes, and coordination. Blood and urine studies look for infections, metabolic abnormalities, and inflammation. A spinal tap tests for proteins relating to ALS or signs of infection or inflammation. Electrodiagnostic tests, such as electromyography and nerve conduction velocity, indicate the health of nerves and muscles. Muscle and nerve biopsies may also be performed to look for signs of damage or disease [2].

X-rays and other imaging studies can identify compressed nerves or issues with the spinal cord [3]. Once the doctor has these results, they may refer the person to a neurologist or ALS specialist for further evaluation and diagnosis.

Current Treatments for ALS

ALS is a progressive condition with no cure, but treatments and therapies can help slow the progression of the disease, manage symptoms, and improve quality of life. The primary FDA-approved medications are Riluzole and Edaravone (Radicava).

Riluzole may slow disease progression by reducing damage to motor neurons and prolonging survival by a few months, especially in patients with better lung function (FVC > 60%) and disease duration under 5 years. It is taken orally but requires regular liver monitoring due to potential side effects like fatigue and nausea [4].

Edaravone (Radicava) is administered via intravenous infusion and may slow functional decline in selected patients, particularly those with early-stage disease, good lung function (FVC > 80%), and relatively preserved functional scores. It may be used alongside Riluzole [4].

Emerging treatments in trials include ATH-1105, an investigational oral small molecule drug designed to modulate neurotrophic factors and potentially slow neurodegeneration [5]. NP001 (sodium chlorite), a therapy targeting inflammation, is moving into Phase 3 trials focusing on lung function as a measure of efficacy [6]. Stem cell therapies aim to reduce neuroinflammation and support motor neuron health via immunomodulation, such as expanding the patient’s own T-regulatory cells to create a more protective environment against neuron degeneration [7]. Gene therapies with broad neuroprotective mechanisms are under investigation to address both genetic and sporadic ALS forms, though these are still experimental [8].

Overall, the current treatments help slow ALS progression modestly, mainly by protecting motor neurons from further damage and reducing harmful inflammation, thus prolonging survival and maintaining function for as long as possible. Multidisciplinary care, including respiratory support and nutritional management, also plays a critical role in improving quality of life [9][10].

As ALS progresses, muscles weaken until they ultimately become paralyzed, and the person cannot move or breathe. However, early diagnosis and treatment can help slow the progression of the disease, reduce symptoms, and improve quality of life. It is essential to consult a healthcare professional for further information and guidance.

References:

  1. Amyotrophic Lateral Sclerosis (ALS)
  2. ALS: Diagnosis, Treatment, and Care
  3. ALS: Diagnosis and Treatment
  4. ALS Medications
  5. ATH-1105
  6. NP001 (sodium chlorite) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
  7. Stem Cell Therapies for ALS
  8. Gene Therapies for ALS
  9. ALS Treatment and Care
  10. Multidisciplinary Care for ALS

Read also:

Latest